Top Markets
#1 Black Phoenix Black Phoenix +830.60%
#2 YFSX YFSX +35.49%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.20%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +25.44%
#5 Beam Beam +22.54%
#6 SAFEcoin SAFEcoin +20.74%
#7 pipedog pipedog +18.64%
#8 Magma Finance Magma Finance +17.22%
#9 THORChain THORChain +15.82%
#10 Nosana Nosana +15.79%
Coin of the day
Black Phoenix Black Phoenix
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
CymaBay Therapeutics, Inc. CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc.

CBAY
Pozycja w akcjach #6080
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Cena akcji
$32.48
Ostatnia synchronizacja: 2024-03-25
Kapitalizacja rynkowa
$2.24B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel CymaBay Therapeutics, Inc. (CBAY)

Kategoria

Healthcare
Historia ceny akcji dla CymaBay Therapeutics, Inc. (CBAY)
Najwyższa cena zamknięcia: $32.39 dnia 2024-03-01

Najniższa cena zamknięcia: $9.00 dnia 2014-02-01
Historia cen akcji firmy CymaBay Therapeutics, Inc. od 2014 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2024 47.52%
2023 374.76%
2022 35.77%
2021 -49.78%
2020 272.39%
2019 -77.25%
2018 -6.63%
2017 374.80%
2016 15.85%
2015 -81.43%
2014 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.51 41.23%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.06K 49.60%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.63 -12.65%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $139.24 454.72%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $765.25 7.19%
CH